Диффузионно-взвешенная магнитно-резонансная томография как альтернатива позитронно-эмиссионной томографии, совмещенной с компьютерной томографией, с ¹⁸F-фтордезоксиглюкозой у пациентов с лимфомами. Обзор литературы и клинические наблюдения

   Диффузионно‑взвешенная магнитно‑резонансная томография может стать альтернативой традиционным методам, таким как компьютерная томография и позитронно‑эмиссионная томография, совмещенная с компьютерной томографией, с ¹⁸F‑фтордезоксиглюкозой. В статье проанализированы не только преимущества метода, но и недостатки и «подводные камни», с которыми приходится сталкиваться врачу‑диагносту. Представлены данные собственных исследований о применении диффузионно‑взвешенной магнитно‑резонансной томографии всего тела у пациентов с лимфомами.

1. Рукавицын О.А., Троян В.Н., Крюков Е.В. и др. Лучевая диагностика при заболеваниях системы крови. М.: ГЭОТАР­ Медиа, 2021. 224 с. DOI: 10.33029/9704­6333­8­DIA­2021­1­224

2. Рукавицын О.А., Удальева В.Ю., Агеева Т.А. и др. Гематология : национальное руководство. 2-­е изд., перераб. и доп. М.: ГЭОТАР­-Медиа, 2024. 916 с. DOI: 10.33029/9704­8188­2­GEM­2024­1­916

3. Glockner J.F., Hu H.H., Stanley D.W. et al. Parallel MR imaging: a user’s guide. Radiographics 2005;25(5):1279–97. DOI: 10.1148/rg.255045202

4. Ballon D., Watts R., Dyke J.P. et al. Imaging therapeutic response in human bone marrow using rapid whole­body MRI. Magn Reson Med 2004;52(6):1234–8. DOI: 10.1002/mrm.20291

5. De Bazelaire C., de Kerviler E. From multislice CT to whole­body biomarker imaging in lymphoma patients. Eur Radiol 2011;21(3):555–8. DOI: 10.1007/s00330­010­2035­9

6. Carbone P.P., Kaplan H.S., Musshoff K. et al. Report of the committee on Hodgkin’s disease staging classification. Cancer Res 1971;31(11):1860–1.

7. Cheson B.D. Staging and response assessment in lymphomas: the new Lugano classification. Chin Clin Oncol 2015;4(1):5. DOI: 10.3978/j.issn.2304­3865.2014.11.03

8. Cheson B.D., Fisher R.I., Barrington S.F. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non­Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014;32(27):3059–68. DOI: 10.1200/JCO.2013.54.8800

9. Brenner D., Elliston C., Hall E. et al. Estimated risks of radiation-induced fatal cancer from pediatric CT. AJR Am J Roentgenol 2001;176(2):289–96. DOI: 10.2214/ajr.176.2.1760289

10. Mathews J.D., Forsythe A.V., Brady Z. et al. Cancer risk in 680,000 people exposed to computed tomography scans in childhood or adolescence: data linkage study of 11 million Australians. BMJ 2013;346:f2360. DOI: 10.1136/bmj.f2360

11. Jerusalem G., Beguin Y., Najjar F. et al. Positron emission tomography (PET) with ¹⁸F­fluorodeoxyglucose (18F­FDG) for the staging of low­grade non­Hodgkin’s lymphoma (NHL). Ann Oncol 2001;12(6):825–30. DOI: 10.1023/a:1011169332265

12. Townsend D.W. Multimodality imaging of structure and function. Phys Med Biol 2008;53(4):R1–39. DOI: 10.1088/0031­9155/53/4/R01

13. Kwee T.C., Takahara T., Ochiai R. et al. Whole­body diffusion-weighted magnetic resonance imaging. Eur J Radiol 2009;70(3):409–17. DOI: 10.1016/j.ejrad.2009.03.054

14. Darge K., Jaramillo D., Siegel M.J. Whole­body MRI in children: current status and future applications. Eur J Radiol 2008;68(2): 289–98. DOI: 10.1016/j.ejrad.2008.05.018

15. Wong F.C., Kim E.E. A review of molecular imaging studies reaching the clinical stage. Eur J Radiol 2009;70(2):205–11. DOI: 10.1016/j.ejrad.2009.01.049

16. Lin C., Luciani A., Itti E. et al. Whole­body diffusion­weighted magnetic resonance imaging with apparent diffusion coefficient mapping for staging patients with diffuse large B­cell lymphoma. Eur Radiol 2010;20(8):2027–38. DOI: 10.1007/s00330­010­1758­y

17. Dudeck O., Zeile M., Pink D. et al. Diffusion­weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft­tissue sarcomas. J Magn Reson Imaging 2008;27(5):1109–13. DOI: 10.1002/jmri.21358

18. Wu X., Kellokumpu­Lehtinen P.L., Pertovaara H. et al. Diffusion-weighted MRI in early chemotherapy response evaluation of patients with diffuse large B­cell lymphoma – a pilot study: comparison with 2­-deoxy­2-­fluoro-­D­glucose­positron emission tomography/computed tomography. NMR Biomed 2011;24(10):1181–90. DOI: 10.1002/nbm.1689

19. Chen Y., Zhong J., Wu H., Chen N. The clinical application of whole­body diffusion­weighted imaging in the early assessment of chemotherapeutic effects in lymphoma: the initial experience. Magn Reson Imaging 2012;30(2):165–70. DOI: 10.1016/j.mri.2011.09.019

20. Gu J., Chan T., Zhang J. et al. Whole­body diffusion­weighted imaging: the added value to whole­body MRI at initial diagnosis of lymphoma. AJR Am J Roentgenol 2011;197(3):W384–91. DOI: 10.2214/AJR.10.5692

21. Stéphane V., Samuel B., Vincent D. et al. Comparison of PET­CT and magnetic resonance diffusion weighted imaging with body suppression (DWIBS) for initial staging of malignant lymphomas. Eur J Radiol 2013;82(11):2011–7. DOI: 10.1016/j.ejrad.2013.05.042

22. Van Ufford H.M., Kwee T.C., Beek F.J. et al. Newly diagnosed lymphoma: initial results with whole­body T1-­weighted, STIR, and diffusion­weighted MRI compared with 18F­FDG PET/CT. AJR Am J Roentgenol 2011;196(3):662–9. DOI: 10.2214/AJR.10.4743

23. Padhani A.R., Koh D.M., Collins D.J. Whole­body diffusion-weighted MR imaging in cancer: current status and research directions. Radiology 2011;261(3):700–18. DOI: 10.1148/radiol.11110474

24. Le Bihan D., Poupon C., Amadon A., Lethimonnier F. Artifacts and pitfalls in diffusion MRI. J Magn Reson Imaging 2006;24(3):478–88. DOI: 10.1002/jmri.20683

25. Nasu K., Kuroki Y., Sekiguchi R. et al. Measurement of the apparent diffusion coefficient in the liver: is it a reliable index for hepatic disease diagnosis? Radiat Med 2006;24(6):438–44. DOI: 10.1007/s11604­006­0053­y

26. Koh D.M., Padhani A.R. Diffusion­weighted MRI: a new functional clinical technique for tumour imaging. Br J Radiol 2006;79(944):633–5. DOI: 10.1259/bjr/29739265

27. Connors J.M. State­of­the­art therapeutics: Hodgkin’s lymphoma. J Clin Oncol 2005;23(26):6400–8. DOI: 10.1200/JCO.2005.05.016

28. Eissa L., Abdel Razek A.A.K., Helmy E. Arterial spin labeling and diffusion­weighted MR imaging: utility in differentiating idiopathic orbital inflammatory pseudotumor from orbital lymphoma. Clin Imaging 2021;71:63–8. DOI: 10.1016/j.clinimag.2020.10.057

29. Eraky A.M., Beck R.T., Treffy R.W. et al. Role of advanced MR imaging in diagnosis of neurological malignancies: current status and future perspective. J Integr Neurosci 2023;22(3):73. DOI: 10.31083/j.jin2203073

30. Giraudo C., Simeone R., Fosio M. et al. Diagnostic value of PET/MR with DWI for Burkitt lymphoma. Diagnostics (Basel) 2021;11(10):1867. DOI: 10.3390/diagnostics11101867

31. Hwang S., Panicek D.M. Magnetic resonance imaging of bone marrow in oncology, Part 2. Skeletal Radiol 2007;36(11):1017–27. DOI: 10.1007/s00256­007­0308­4

32. Liu Y., Wang Y., Wang P., Yu Q. A retrospective study to evaluate the CT and MR imaging findings of non­Hodgkin’s lymphoma affecting the jaw bones. Oral Radiol 2022;38(4):509–16. DOI: 10.1007/s11282­021­00582­y

33. Sharma S., Leung W.H., Deqing P. et al. Osteonecrosis in children after allogeneic hematopoietic cell transplantation: study of prevalence, risk factors and longitudinal changes using MR imaging. Bone Marrow Transplant 2012;47(8):1067–74. DOI: 10.1038/bmt.2011.234

34. Siegel R.L., Miller K.D., Wagle N.S. et al. Cancer statistics, 2023. CA Cancer J Clin 2023;73(1):17–48. DOI: 10.3322/caac.21763

35. Thuy T.T.M., Trang N.T.H., Vy T.T. et al. Role of diffusion­weighted MRI in differentiation between benign and malignant anterior mediastinal masses. Front Oncol 2022;12:985735. DOI: 10.3389/fonc.2022.985735

36. Toledano­Massiah S., Luciani A., Itti E. et al. Whole­body diffusion­weighted imaging in Hodgkin lymphoma and diffuse large B­cell lymphoma. Radiographics 2015;35(3):747–64. DOI: 10.1148/rg.2015140145

37. Winzer R., Hoberück S., Zöphel K. et al. Diffusion-­weighted MRI for initial staging in Hodgkin’s lymphoma: comparison with FDG PET. Eur J Radiol 2020;123:108775. DOI: 10.1016/j.ejrad.2019.108775